Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2024

Stock-Based Compensation

Schedule of RSA activity and related information

			Weighted-
	Number of		Average Grant-Date
	Shares		Fair Value
Unvested as of December 31, 2023		27,199	$	2.71
Vested		(6,027)		0.01
Repurchased		(21,172)		3.48
Unvested as of September 30, 2024		—	$	—

Schedule of stock option activity and related information

					Weighted-Average		Aggregate
	Number of		Weighted-Average		Remaining		Intrinsic
	Shares		Exercise Price		Contractual Term		Value
						(in years)		(in thousands)
Balance as of December 31, 2023		2,382,933	$	8.51			$	8,084
Granted		6,363,022		14.86
Exercised		(25,953)		7.56				78
Forfeited or cancelled		(89,927)		9.21
Balance outstanding as of September 30, 2024		8,630,075	$	13.19		9.42	$	32,545
Options vested and exercisable as of September 30, 2024		1,017,323	$	7.00		7.71	$	10,093
Options vested and expected to vest as of September 30, 2024		8,630,075	$	13.19		9.42	$	32,545

Schedule of stock-based compensation expense as reflected in condensed consolidated statements of operations and comprehensive loss

The following table presents stock-based compensation expense as reflected in the Company’s condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023 (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Research and development	$	1,257	$	510	$	2,378	$	1,040
General and administrative		1,586		493		2,948		1,320
Total stock-based compensation expense	$	2,843	$	1,003	$	5,326	$	2,360